Liminal BioSciences surges on sale of priority review voucher

Liminal BioSciences

09/08/2021 13:24

** U.S.-listed shares of Canadian drugmaker Liminal
BioSciences Inc  LMNL.O  jump 20% premarket, set to open at a
two-week high of $3.44
    ** Co's unit sells its rare pediatric disease priority
review voucher (PRV) for $105 mln as part of its sale of
remaining plasma-derived therapeutics business to Kedrion
Biopharma  urn:newsml:reuters.com:*:nFWN2PG0UU
    ** PRV, which helps in expediting FDA approvals, was granted
by FDA after approval of Ryplazim in June for treatment of
patients with hypoplasminogenia
    ** Hypoplasminogenia is a disorder that can impair normal
tissue and organ function and may lead to blindness
    ** LMNL set for best session in two months
    ** Stock down 32% YTD as of last close
    

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))